Literature DB >> 2861618

Characterization of the bupropion cue in the rat: lack of evidence for a dopaminergic mechanism.

R D Blitzer, R E Becker.   

Abstract

Using a two-lever operant task rats were trained to discriminate 40 mg/kg IP of bupropion from saline. Despite bupropion's established dopaminergic activity in vitro and in vivo, it was found that the bupropion cue was neither mimicked by the dopaminergic drugs L-DOPA and bromocriptine nor blocked by a variety of neuroleptics (haloperidol, thioridazine, and thiothixene). In addition, bupropion was active in attenuating the behavior-suppressing effects of haloperidol, unlike amphetamine and the atypical antidepressants, nomifensine and viloxazine. The bupropion cue was not mimicked or disrupted by adrenergic or serotonergic drugs, but it did generalize to some stimulants (amphetamine, cocaine and caffeine) as well as to nomifensine and viloxazine. The generalizations were blocked by neuroleptics. These data indicate that bupropion's cue properties may not be based on its ability to modulate dopaminergic receptor activity. The possible involvement of phenylethylamine in the bupropion cue is also discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861618     DOI: 10.1007/bf00428409

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Bupropion hydrochloride ((+/-) alpha-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent.

Authors:  F E Soroko; N B Mehta; R A Maxwell; R M Ferris; D H Schroeder
Journal:  J Pharm Pharmacol       Date:  1977-12       Impact factor: 3.765

2.  The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings].

Authors:  H Canning; D Goff; M J Leach; A A Miller; J E Tateson; P L Wheatley
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

Review 3.  Viloxazine and neurotransmitter function.

Authors:  D T Greenwood
Journal:  Adv Biochem Psychopharmacol       Date:  1982

4.  Two multicenter studies of the antidepressant effects of bupropion HCl versus placebo.

Authors:  W C Stern; N Harto-Truax
Journal:  Psychopharmacol Bull       Date:  1980-07

5.  Relationship between bupropion disposition and dopamine uptake inhibition in rats and mice.

Authors:  R F Butz; R M Welch; J W Findlay
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

6.  The lack of effect of bupropion HCL (Wellbatrin) on the secretion of growth hormone and prolactin in humans.

Authors:  G Laakmann; N Hoffmann; E Hofschuster
Journal:  Life Sci       Date:  1982-05-17       Impact factor: 5.037

7.  beta-Phenylethylamine reversal of chlorpromazine-induced activation of striatal tyrosine hydroxylase and catalepsy.

Authors:  D M Stoff; K Gale
Journal:  Brain Res       Date:  1981-05-04       Impact factor: 3.252

8.  Perceptual changes with bupropion, a novel antidepressant.

Authors:  R E Becker; R L Dufresne
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

9.  Clinical efficacy of the new antidepressant bupropion (Wellbutrin) [proceedings].

Authors:  A E Halaris; W Stern; N Harto-Truax
Journal:  Psychopharmacol Bull       Date:  1981-01

10.  Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors: a possible role for beta-phenylethylamine in the cocaine cue.

Authors:  F C Colpaert; C J Niemegeers; P A Janssen
Journal:  Pharmacol Biochem Behav       Date:  1980-10       Impact factor: 3.533

View more
  7 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens.

Authors:  J C Barnes; B Costall; A M Domeney; R J Naylor
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine.

Authors:  D J Heal; A T Frankland; J Gosden; L J Hutchins; M R Prow; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Pavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine.

Authors:  Jamie L Wilkinson; Chia Li; Rick A Bevins
Journal:  Addict Biol       Date:  2008-12-12       Impact factor: 4.280

Review 6.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 7.  Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.

Authors:  Sally L Huskinson; Jennifer E Naylor; James K Rowlett; Kevin B Freeman
Journal:  Neuropharmacology       Date:  2014-03-22       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.